Publication Cover
Reproductive Health Matters
An international journal on sexual and reproductive health and rights
Volume 13, 2005 - Issue 26: The abortion pill
1,504
Views
0
CrossRef citations to date
0
Altmetric
Round Up

Medical Abortion

Pages 165-167 | Published online: 12 Nov 2005

References

  • Gibson L. WHO puts abortifacients on its essential drug list [News Roundup]. BMJ. 2005; 331: 68.
  • Fiala C, Winikoff B, Helstrfm L, et al. Acceptability of home-use of misoprostol in medical abortion. Contraception. 2004; 70: 387–92.
  • Shah R, Baji S, Kalgutkar S. Attitudes about medical abortion among Indian women. International Journal of Gynecology and Obstetrics. 2005; 89: 69–70.
  • Planned Parenthood Wisconsin develops communication tools that work. Mife Matters. 2005;11. : 10.
  • Murthy AS, Creinin MD, Harwood B, et al. A pilot study of mifepristone and misoprostol administered at the same time for abortion up to 49 days gestation. Contraception. 2005; 71: 333–36.
  • Shannon C, Brothers LP, Philip NM, et al. Infection after medical abortion: a review of the literature. Contraception. 2004; 70: 183–90.
  • Grimes DA. Risks of mifepristone abortion in context [Commentary]. Contraception. 2005; 71: 161.
  • Cowett AA, Cohen LS, Lichtenberg ES, et al. Ultrasound evaluation of the endometrium after medical termination of pregnancy. Obstetrics and Gynecology. 2004; 103(5): 871–75.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.